All In Biotech

Drug Trial Radar · NCT00563381

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Effect of Inhalation of Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients (a Randomised, Double-blind, Double-dummy, Parallel Group, One-year Study).

Last checked: Nov 19, 2026Latest source record: Dec 24, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 7,376 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

7,376

Actual

Start

Jan 2008

Primary completion

Apr 2010

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
Collaborators
Pfizer
First posted
Nov 26, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, double-blind, double-dummy, multinational, multicentre, parallel group trial comparing tiotropium (18 mcg) inhalation capsule via HandiHaler and salmeterol (50 mcg) via MDI in patients with COPD. There will be a two-week run-in period followed by a 52-week randomised treatment phase. Patients who withdraw prematurely from trial medication will be encouraged to remain in the trial and participate in follow-up telephone contacts until their predicted normal exit date from the trial (i.e. 52 weeks after taking the first dose of randomised treatment). The phone calls will be made at all scheduled visits. The primary objective of this study is to compare the effect of tiotropium (18 mcg) inhalation capsule via HandiHaler with that of salmeterol (50 mcg) via MDI on COPD exacerbations. The primary endpoint is time to first COPD exacerbation during the 52 week randomised treatment period. A COPD exacerbation will be defined as a complex of respiratory events / symptoms (increase or new onset) of more than one of the following: cough, sputum, wheezing, dyspnoea or chest tightness with at least one symptom lasting at least three days requiring treatment with antibiotics and/or systemic steroids and/or hospitalisation. The onset of an exacerbation is defined as the onset of the first new or increased reported symptom. The end of the exacerbation should be recorded as defined by the investigator. Only COPD exacerbations with onset during randomised treatment will be included in the analysis.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • Tiotropium bromideDrug

    18 mcg/daily

  • SalmeterolDrug

    100 mcg/daily

  • Placebo SalmeterolDrug

    Placebo identical to Salmeterol device

  • Placebo TiotropiumDrug

    Placebo identical to Tiotropium device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. First Occurrence of (Moderate or Severe) COPD ExacerbationTime frame: 52 weeks

Locations

752 sites in 25 countries. Site status is shown where the registry gives one.

  • 205.389.1020 Boehringer Ingelheim Investigational Site

    Feldbach, Austria

  • 205.389.1010 Boehringer Ingelheim Investigational Site

    Feldkirch, Austria

  • 205.389.1003 Boehringer Ingelheim Investigational Site

    Gänserndorf, Austria

  • 205.389.1011 Boehringer Ingelheim Investigational Site

    Grimmenstein/Hochegg, Austria

  • 205.389.1005 Boehringer Ingelheim Investigational Site

    Hallein, Austria

  • 205.389.1023 Boehringer Ingelheim Investigational Site

    Linz, Austria

  • 205.389.1001 Boehringer Ingelheim Investigational Site

    Mittersill, Austria

  • 205.389.1027 Boehringer Ingelheim Investigational Site

    Salzburg, Austria

  • 205.389.1026 Boehringer Ingelheim Investigational Site

    Schlüsslberg, Austria

  • 205.389.1016 Boehringer Ingelheim Investigational Site

    Spittal/Drau, Austria

  • 205.389.1022 Boehringer Ingelheim Investigational Site

    Steyr, Austria

  • 205.389.1002 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 205.389.1006 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 205.389.1014 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 205.389.1018 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 205.389.1021 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 205.389.1029 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 205.389.1017 Boehringer Ingelheim Investigational Site

    Zwettl Stadt, Austria

  • 205.389.1120 Boehringer Ingelheim Investigational Site

    Buizingen, Belgium

  • 205.389.1124 Boehringer Ingelheim Investigational Site

    Cerexhe-Heuseux, Belgium

  • 205.389.1116 Boehringer Ingelheim Investigational Site

    Chenée (Liége), Belgium

  • 205.389.1121 Boehringer Ingelheim Investigational Site

    Dour, Belgium

  • 205.389.1113 Boehringer Ingelheim Investigational Site

    Gembloux, Belgium

  • 205.389.1117 Boehringer Ingelheim Investigational Site

    Gozée, Belgium

  • 205.389.1126 Boehringer Ingelheim Investigational Site

    Hasselt, Belgium

  • 205.389.1129 Boehringer Ingelheim Investigational Site

    Natoye, Belgium

  • 205.389.1130 Boehringer Ingelheim Investigational Site

    Quaregnon, Belgium

  • 205.389.1115 Boehringer Ingelheim Investigational Site

    Thuillies, Belgium

  • 205.389.1107 Boehringer Ingelheim Investigational Site

    Wetteren, Belgium

  • 205.389.3911 Boehringer Ingelheim Investigational Site

    Pazardzhik, Bulgaria

  • 205.389.3903 Boehringer Ingelheim Investigational Site

    Plovdiv, Bulgaria

  • 205.389.3915 Boehringer Ingelheim Investigational Site

    Plovdiv, Bulgaria

  • 205.389.3918 Boehringer Ingelheim Investigational Site

    Rousse, Bulgaria

  • 205.389.3914 Boehringer Ingelheim Investigational Site

    Sliven, Bulgaria

  • 205.389.3902 Boehringer Ingelheim Investigational Site

    Sofia, Bulgaria

  • 205.389.3906 Boehringer Ingelheim Investigational Site

    Sofia, Bulgaria

  • 205.389.3907 Boehringer Ingelheim Investigational Site

    Sofia, Bulgaria

  • 205.389.3908 Boehringer Ingelheim Investigational Site

    Stara Zagora, Bulgaria

  • 205.389.3916 Boehringer Ingelheim Investigational Site

    Troyan Municipality, Bulgaria

  • 205.389.3912 Boehringer Ingelheim Investigational Site

    Varna, Bulgaria

Showing 40 of 752 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.